Media

  • Email
  • Help

Information for you

On this page, we highlight information of partcular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union.

For more information and details relevant for media, see our News & events section. 

For enquiries from media, please contact the EMA press office

Featured information

News for media

Events of interest

  • 25/10/2017

    EMA

    European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

    European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group (CG) in 2017 welcomed members of the working groups and representatives of the registered networks. The focus of this meeting was on updates from the working groups on their work since the last update during the face to face 22017 annual workshop of the European network of paediatric research at the European Medicines Agency. The CG also reviewed proposals for the pam-European IMI2 paediatric network and contributions to the public consultation on the reflection pager on the use of extrapolation of efficacy and safety in medicine development. ... Read more

  • 22/11/2017

    EMA

    European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

    The last meeting of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group in 2017 saw the review of the mandate of the working groups, the endorsement to new network members. The group also discussed the agenda of the 2018 face to face meeting. ... Read more

  • 15/12/2017

    EMA

    Fourteenth joint European Medicines Agency/European network for Health Technology Assessment dialogue meeting

    The EMA and EUnetHTA have been holding regular dialogue since 2010. The key topics of this meeting are concepts related to orphan medicines (significant benefit vs relative effectiveness), opportunities for collaboration on horizon scanning, reflections on the concept of evidence transfer / extrapolation, principles of the working of the indication as well as ongoing initiatives on post-licensing evidence generation. A report from the meeting will be published later. ... Read more

  • 15/11/2017

    EMA

    Second industry stakeholder platform on research and development support

    This is the second event in a series of (semi-)annual meetings between regulators and representatives of industry stakeholder organisations. It addresses all areas of product development support, from scientific advice, over specifics for paediatric and orphan medicines and to innovation support. This platform aims to provide an opportunity for both general updates and more focused discussions on specific processes or issues to support continuous improvement, and generally to foster a constructive dialogue with industry stakeholders. Registration by invitation only. ... Read more

  • 24/10/2017 - 25/10/2017

    EMA

    Third tripartite meeting held between EMA, PMDA and FDA to discuss regulatory approaches for the evaluation of antibacterial agents

    This meeting built on the work of previous two meetings between the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the way these regulators approach the evaluation of antimicrobials, aiming at identifying further areas for convergence. The three agencies agreed to further align how clinical trials should be designed to study the effects of new antibiotics in certain indications, such as uncomplicated gonorrhoea or uncomplicated urinary tract infections. They also committed to working together to explore how to better streamline paediatric development of new antibacterial agents and discussed he importance of characterising the pharmacokinetic-pharmacodynamic relationship and monitoring the benefit-risk balance throughout the medicine lifecycle. The agencies plan to meet again in 2018. ... Read more

  • See all Events of interest

Information for:

Find information for...